GlassScriptPhysician profile
Raghad Jalil
NPI 1568613743
$3,578.64
in general payments reported to CMS, 2019-2025
29 companies · $829 in 2025
The $829 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $303 · 2021: $124 · 2022: $108 · 2023: $840 · 2024: $999 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,466 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.30 |
| Education | $202.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $397.99 | 2020-2025 | Austedo, Ajovy, Austedo Xr |
| Abbvie INC. | $347.13 | 2023-2025 | |
| Lilly USA, LLC | $281.87 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Alexion Pharmaceuticals, INC. | $266.72 | 2019-2024 | Ultomiris, Soliris |
| Biogen, INC. | $254.03 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $247.78 | 2019-2025 | |
| Emd Serono, INC. | $222.10 | 2019-2025 | Mavenclad |
| Eisai INC. | $205.32 | 2019-2025 | |
| Neurelis, INC. | $145.60 | 2023-2025 | Valtoco |
| Argenx US, INC. | $140.39 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $121.66 | 2023-2025 | Briviact, Rystiggo |
| Genzyme Corporation | $114.52 | 2022-2023 | |
| Tanabe Pharma America, INC. | $111.80 | 2021-2025 | Radicava |
| Novartis Pharmaceuticals Corporation | $109.22 | 2024-2025 | |
| Lundbeck LLC | $83.49 | 2023-2025 | Vyepti, Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $70.18 | 2023-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $62.94 | 2023-2025 | Xeomin, Inbrija |
| Amneal Pharmaceuticals LLC | $60.08 | 2023-2025 | Rytary, Ongentys |
| Tg Therapeutics, INC. | $53.92 | 2025 | |
| Ani Pharmaceuticals, INC. | $44.80 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $43.12 | 2019-2025 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $41.95 | 2023 | Rexulti |
| Sk Life Science, INC. | $29.55 | 2023 | |
| Currax Pharmaceuticals LLC | $27.96 | 2024 | Onzetra Xsail, Contrave |
| Nevro Corp. | $26.11 | 2024 | Senza |
| Alnylam Pharmaceuticals INC. | $22.04 | 2025 | Amvuttra |
| Acadia Pharmaceuticals INC | $18.90 | 2023 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $14.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghad Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.